Evaluation of the Safety, Tolerability and Pharmacokinetics of TUL108 for Injection in Healthy Participants (SAD/ MAD)
A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of TUL108 for Injection After Single and Multiple Intravenous Infusions in Healthy Participants.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Primary Objective:
To evaluate the safety and tolerability of single and multiple intravenous (IV) infusion of TUL108 in healthy participants.
Secondary Objectives:
- To evaluate the pharmacokinetic (PK) profiles of TUL108 following single and multiple IV infusion in healthy participants.
- To evaluate the effect of IV infusion of TUL108 on QT interval.
- To preliminarily evaluate the human biotransformation and mass balance characteristics following IV infusion of TUL108.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Jing Zhang
- Phone Number: +86-021-52887926
- Email: 13816357098@163.com
Study Locations
-
-
-
Shanghai, China
- Huashan Hospital Affiliated to Fudan University
-
Contact:
- Jing Zhang
- Phone Number: +86-021-52887926
- Email: 13816357098@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must sign the informed consent form prior to the study, fully understand the study, procedures, and potential adverse reactions, and be voluntary participate in and able to complete the study as required by the protocol.
- Male or female participants aged 18-45 years (inclusive).
- Body weight of not less than 50.00 kg for male participants and 45.00 kg for female participants with body mass index (BMI) within the range of 19.0-27.0 kg/m2 (inclusive).
- Female participants of childbearing potential, or male participants whose partners are of childbearing potential, must have no plans for pregnancy, sperm/egg donation from signing the informed consent until 3 months after the last dose, and must be voluntary to use highly effective contraception (including their partners) (non-pharmacological contraception is required during the study).
Exclusion Criteria:
- Having a clinically significant severe disease (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, pulmonary, immunological, psychiatric, or cardiovascular and cerebrovascular diseases) within 12 months prior to screening.
- Participants with clinically significant abnormalities in laboratory tests, physical examination, vital signs, electrocardiogram (ECG), posteroanterior chest X-ray, or abdominal ultrasound.
- Female participants who are pregnant or lactating.
- Participants with acute illness or requiring concomitant medication from screening to the first dose.
- Participants who are unable to tolerate venipuncture or have a history of needle phobia or hemophobia.
- Participants who are unsuitable for the study as assessed by the investigator due to any other factors.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part1: TUL108
A single ascending dose (SAD) of intravenous (IV) TUL108 (50mg~1500mg)
|
50 mg、125 mg、250 mg、500 mg、1000 mg、1500 mg
125 mg、250 mg、500 mg
|
|
Placebo Comparator: Part1: Placebo
Placebo
|
0.9% Sodium Chloride Injection
|
|
Experimental: Part2: TUL108
A multiple ascending dose (MAD) of intravenous (IV) TUL108 (125 mg~500mg q8h)
|
50 mg、125 mg、250 mg、500 mg、1000 mg、1500 mg
125 mg、250 mg、500 mg
|
|
Placebo Comparator: Part2: Placebo
Placebo
|
0.9% Sodium Chloride Injection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Part 1: Incidence of adverse events (AEs), serious adverse events (SAEs) etc.
Time Frame: Day 1 to Day 4
|
Day 1 to Day 4
|
|
Part 2: Incidence of adverse events (AEs), serious adverse events (SAEs) etc.
Time Frame: Day 1 to Day 11
|
Day 1 to Day 11
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jing Zhang, Huashan Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- TUL-TUL108 (Ⅰ-1) 202603
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.